207 related articles for article (PubMed ID: 29631965)
1. Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Grilley-Olson JE; Weiss J; Ivanova A; Villaruz LC; Moore DT; Stinchcombe TE; Lee C; Shan JS; Socinski MA
Clin Lung Cancer; 2018 Jul; 19(4):e481-e487. PubMed ID: 29631965
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD
J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
[TBL] [Abstract][Full Text] [Related]
4. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.
Doebele RC; Spigel D; Tehfe M; Thomas S; Reck M; Verma S; Eakle J; Bustin F; Goldschmidt J; Cao D; Alexandris E; Yurasov S; Camidge DR; Bonomi P
Cancer; 2015 Mar; 121(6):883-92. PubMed ID: 25377507
[TBL] [Abstract][Full Text] [Related]
5. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience.
Malhotra B; Evans T; Weiss J; Eaby B; Stonehouse-Lee S; Sherry V; Langer CJ
Clin Lung Cancer; 2010 May; 11(3):192-7. PubMed ID: 20439196
[TBL] [Abstract][Full Text] [Related]
7. Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients.
Takeoka H; Yamada K; Naito Y; Matsuo N; Ishii H; Tokito T; Azuma K; Ichiki M; Hoshino T
Anticancer Res; 2018 Jun; 38(6):3779-3784. PubMed ID: 29848743
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Rizvi NA; Hellmann MD; Brahmer JR; Juergens RA; Borghaei H; Gettinger S; Chow LQ; Gerber DE; Laurie SA; Goldman JW; Shepherd FA; Chen AC; Shen Y; Nathan FE; Harbison CT; Antonia S
J Clin Oncol; 2016 Sep; 34(25):2969-79. PubMed ID: 27354481
[TBL] [Abstract][Full Text] [Related]
10. Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Shiraishi Y; Kishimoto J; Tanaka K; Sugawara S; Daga H; Hirano K; Azuma K; Hataji O; Hayashi H; Tachihara M; Mitsudomi T; Seto T; Nakagawa K; Yamamoto N; Okamoto I
Clin Lung Cancer; 2020 Sep; 21(5):472-476. PubMed ID: 32381420
[TBL] [Abstract][Full Text] [Related]
11. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer.
Digumarti R; Bapsy PP; Suresh AV; Bhattacharyya GS; Dasappa L; Shan JS; Gerber DE
Lung Cancer; 2014 Nov; 86(2):231-6. PubMed ID: 25236982
[TBL] [Abstract][Full Text] [Related]
12. Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer.
Weiss JM; Villaruz LC; O'Brien J; Ivanova A; Lee C; Olson JG; Pollack G; Gorman R; Socinski MA; Stinchombe TE
Clin Lung Cancer; 2016 Mar; 17(2):128-32. PubMed ID: 26774201
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer.
Takeoka H; Yamada K; Azuma K; Zaizen Y; Yamashita F; Yoshida T; Naito Y; Okayama Y; Miyamoto M; Hoshino T
Jpn J Clin Oncol; 2014 May; 44(5):472-8. PubMed ID: 24688087
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.
Tamiya M; Tamiya A; Kaneda H; Nakagawa K; Yoh K; Goto K; Okamoto H; Shimokawa T; Abe T; Tanaka H; Daga H; Takeda K; Hirashima T; Atagi S
Med Oncol; 2016 Jan; 33(1):2. PubMed ID: 26603297
[TBL] [Abstract][Full Text] [Related]
16. Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices.
Velcheti V; Hu X; Piperdi B; Burke T
Sci Rep; 2021 Apr; 11(1):9222. PubMed ID: 33911121
[TBL] [Abstract][Full Text] [Related]
17. A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC.
Huang M; Gong Y; Zhu J; Qin Y; Peng F; Ren L; Ding Z; Liu Y; Cai C; Wang Y; Lu Y
Invest New Drugs; 2020 Apr; 38(2):478-484. PubMed ID: 31231786
[TBL] [Abstract][Full Text] [Related]
18. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Yokomura K; Koshimizu N; Sato M; Toyoshima M; Shirai T; Masuda M; Yamada T; Imokawa S; Suda T
Eur J Cancer; 2016 May; 58():30-7. PubMed ID: 26922170
[TBL] [Abstract][Full Text] [Related]
19. Phase II Study of Carboplatin and Pemetrexed in Advanced EGFR-wild-type Non-squamous Non-small Cell Lung Cancer: The Central Japan Lung Study Group Trial 0906.
Kimura T; Taniguchi H; Watanabe N; Saka H; Kogure Y; Shindo J; Ogasawara T; Kojima E; Hasegawa Y; Yamamoto M; Suzuki R; Ando M; Kondo M; Saito H
Anticancer Res; 2016 Apr; 36(4):1767-71. PubMed ID: 27069157
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation and pharmacokinetic study of carboplatin plus pemetrexed for elderly patients with advanced nonsquamous non-small-cell lung cancer: Kumamoto thoracic oncology study group trial 1002.
Sakata S; Sasaki J; Saeki S; Hamada A; Kishi H; Nakamura K; Tanaka H; Notsute D; Sato R; Saruwatari K; Iriki T; Akaike K; Fujii S; Hirosako S; Kohrogi H
Oncology; 2015; 88(4):201-7. PubMed ID: 25502447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
